Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +5.26% and -70.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for ...
Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...
Recursion CEO Chris Gibson is out after 12 years as the ambitious ‘techbio’ company positions itself for its next phase of AI ...
TipRanks on MSN
Recursion Pharmaceuticals Announces New CEO Appointment
Recursion Pharmaceuticals ( ($RXRX) ) has provided an update. Recursion Pharmaceuticals announced significant leadership changes effective January ...
Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...
For years, privacy-focused blockchains were seen as side projects with limited reach. That’s about to change with Zero Knowledge Proof (ZKP). Built as a privacy ...
Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
Looking for a biopharma job in New York? Check out the BioSpace list of eight companies hiring life sciences professionals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback